Liberate Bio Taps CAR-T Veteran to Guide In Vivo Cell Therapy Revolution

BOSTON, MA – July 27, 2026

In a move that signals a pivotal transition from preclinical promise to clinical reality, Liberate Bio has appointed Dr. Steven H. Bernstein, a seasoned physician-scientist with deep roots in approved cell therapies, as its new Chief Medical Officer. The hire is a significant catalyst for the Boston-based firm, which is pioneering a radical new approach to genetic medicine: programming a patient's immune cells directly inside their body. For investors and industry watchers, this appointment is the clearest indicator yet that Liberate Bio is preparing to take its ambitious platform into human trials, a critical step in its quest to disrupt the multi-billion dollar cell therapy market.

Dr. Bernstein joins as the company's lead programs in autoimmune disease and oncology approach their first clinical evaluations. His mandate is clear: to shepherd these novel therapies through the complex and unforgiving landscape of clinical development and regulatory approval. It’s a challenge that requires not just scientific acumen, but the battle-tested judgment that comes from navigating the path to market before.

A Strategic Hire for a Critical Juncture

To understand the significance of this hire, one need only look at Dr. Bernstein’s track record. He comes to Liberate Bio from Regeneron's Cell Medicine Unit, but his most relevant experience may be his tenure as Chief Medical Officer at 2seventy bio. There, he was deeply involved with Abecma, the first FDA-approved CAR-T therapy for multiple myeloma. His work on a landmark therapy that defined the first generation of commercial cell therapies gives him a unique perspective on the very problems Liberate Bio aims to solve.

“Steven is exactly the clinical leader Liberate needs at this moment,” said Dr. Shawn P. Davis, Chief Executive Officer of Liberate Bio, in the company's official statement. “His experience advancing cell therapies across the arc from early development through approval gives us the judgment to translate that biology into disciplined human studies and, ultimately, into medicines that reach far more patients.”

This isn't just about clinical trial design. Dr. Bernstein’s expertise spans translational medicine, regulatory strategy, and clinical operations—the essential pillars required to bridge the gap between a promising molecule and an approved medicine. His background as an academic physician-scientist focused on lymphoma immunobiology further grounds his corporate experience in fundamental science, a crucial asset when dealing with a novel therapeutic modality.

The Promise of In Vivo Programming

The central premise of Liberate Bio is a direct challenge to the status quo of cell therapy. Current approved treatments, like Abecma, are ex vivo therapies. They involve a laborious and costly “vein-to-vein” process: a patient's immune cells are extracted, frozen, and shipped to a centralized manufacturing facility. There, they are genetically engineered and multiplied over several weeks before being shipped back and reinfused into the patient. While life-saving for some, this process creates extreme logistical hurdles, manufacturing bottlenecks, and staggering costs that limit patient access.

Liberate Bio’s approach bypasses this entire paradigm. The company is developing what is essentially an “off-the-shelf” injection that programs immune cells in vivo—directly within the circulation. By engineering lipid nanoparticles (LNPs) to deliver RNA payloads to specific immune cells like monocytes and macrophages, the company can turn them into therapeutic powerhouses without ever removing them from the body.

This is the foundation of its lead CAR-M (Chimeric Antigen Receptor Macrophage) programs. As Dr. Bernstein noted, this method “combines the potency of engineered immune cells with the repeatability and scalability of an RNA medicine.” The potential impact is enormous: a scalable, more accessible, and potentially more affordable class of cell therapies that could reach far broader patient populations across oncology and autoimmune disorders.

RAPTOR™: The AI-Powered Engine Driving Precision Delivery

This ambitious vision rests on the company’s proprietary RAPTOR™ platform, a sophisticated engine designed to solve the biggest problem in genetic medicine: delivery. For years, the field has been hampered by the challenge of getting genetic payloads to specific cells while avoiding the liver, which naturally filters most nanoparticles from the blood.

The RAPTOR™ platform tackles this with a two-pronged strategy. First, it uses high-throughput screening of LNP formulations directly in non-human primates (NHPs), generating real-world biological data on where the particles go. Second, it feeds this massive dataset into an AI-driven design loop, which learns from the in vivo outcomes to design new, optimized LNPs. This creates a powerful feedback cycle between AI-based prediction and biological reality.

The result is a portfolio of LNPs engineered to be myeloid-selective and liver-detargeted. The company has already reported compelling preclinical evidence for this approach, demonstrating that its lead in vivo CAR-M therapy can achieve up to 99% depletion of peripheral B-cells in NHPs at well-tolerated doses. This provides powerful proof-of-concept that immune effector cells can be effectively and safely engineered inside the body, significantly de-risking the upcoming transition to human studies.

Navigating a High-Stakes Landscape

Liberate Bio is not operating in a vacuum. The race to unlock in vivo gene programming is one of the most competitive and well-funded areas in biotechnology. However, the company's focus on myeloid cells and its unique AI-powered NHP screening platform provide a differentiated position. By generating a proprietary dataset based on real-world primate delivery outcomes, the firm is building a formidable moat against competitors relying on more conventional LNP discovery methods.

For the market, the appointment of Dr. Bernstein is a de-risking event. It validates the scientific platform to a degree that attracts top-tier talent and signals that the company is building the infrastructure needed for late-stage development. With a seasoned clinical and regulatory expert at the helm, Liberate Bio is now positioned to translate its groundbreaking science into the rigorous data required by regulators and, eventually, patients. The journey is long and fraught with risk, but the company has just secured an expert guide for its most critical phase. The entire industry will be watching to see if this is the moment the promise of accessible cell therapy begins to be liberated.